Your session is about to expire
← Back to Search
Capecitabine + Radiotherapy for Breast Cancer
Phase 1
Waitlist Available
Led By Bapsi Chakravarthy, MD
Research Sponsored by A Bapsi Chakravarthy, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 7 months
Awards & highlights
Summary
This trial tests a combination of a chemotherapy drug (capecitabine) and radiation therapy for patients with breast cancer that doesn't respond to standard treatments. The treatment aims to attack cancer cells more effectively by disrupting their DNA and using radiation to destroy them. Capecitabine is an oral chemotherapy drug that has shown effectiveness in combination with other treatments, such as docetaxel, in improving survival rates for breast cancer patients.
Eligible Conditions
- Triple Negative Breast Cancer
- Breast Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 7 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 7 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Assess tolerability
Characterize radiation dermatitis secondary to concurrent capecitabine-radiotherapy
Completion of exploratory assessments
+2 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Concurrent Adjuvant Capecitabine and RadiotherapyExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Capecitabine
2013
Completed Phase 3
~3970
Radiotherapy
2017
Completed Phase 3
~2610
Find a Location
Who is running the clinical trial?
A Bapsi Chakravarthy, MDLead Sponsor
Bapsi Chakravarthy, MDPrincipal Investigator - Vanderbilt Medical Center
Vanderbilt-Ingram Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are planning to receive radiation therapy after the main cancer treatment.You can still participate in the trial if you have taken tamoxifen for cancer prevention.
Research Study Groups:
This trial has the following groups:- Group 1: Concurrent Adjuvant Capecitabine and Radiotherapy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger